Sernova Corp T.SVA

Alternate Symbol(s): SEOVF

Healthcare Biotechnology

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.

TSX:SVA - Post by User

Sernova Corp > Biotech

<< Previous

Bullboard Posts

Next >>

Comment by bull1986on May 26, 2021 2:36pm

163 Views

Post# 33269020

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Biotech

The first patient had 2 cell pouch doses and one portal vein top-up. After the second cell pouch dose we saw a ~43% reduction in insulin use! Importantly 0 serve hypoglycemic events. Not to mention the reduction in HbA1C. As you previously mentioned, the pouch seems to work better with less cells. My understanding is islet dosing is being adjusted as the study progresses, hence my belief Sernova is approaching a cure pre top-up. Obviously I'm speculating but keep in mind Sernova has cured diabetes in multiple animal models by adjusting dosing. A certain amount of speculation is necessary is it not?

<< Previous

Bullboard Posts

Next >>

High-growth stock Happy Belly opens first Rosie's Burgers in Alberta